Easy NAPLEX Heart Failure Practice Questions

Concept Explanation

Heart failure is a clinical syndrome characterized by the heart's inability to pump sufficient blood to meet the metabolic demands of the body, often resulting from structural or functional impairments in ventricular filling or ejection. For the NAPLEX, it is essential to distinguish between Heart Failure with Reduced Ejection Fraction (HFrEF), where the left ventricular ejection fraction (LVEF) is $\leq 40\%$, and Heart Failure with Preserved Ejection Fraction (HFpEF), where LVEF is $\geq 50\%$. Management focuses on the "four pillars" of guideline-directed medical therapy (GDMT): Beta-blockers, ACE inhibitors/ARBs/ARNIs, Mineralocorticoid Receptor Antagonists (MRAs), and SGLT2 inhibitors. Understanding the NAPLEX Prep requirements involves mastering drug classes, monitoring parameters like potassium and serum creatinine, and identifying contraindications such as bilateral renal artery stenosis or a history of angioedema.

Pharmacists play a critical role in titrating these medications to target doses proven in clinical trials to reduce mortality. Beyond the four pillars, loop diuretics are utilized for symptom management of fluid overload, while medications like ivabradine or hydralazine/isosorbide dinitrate are reserved for specific patient populations. You can further explore related topics in our Easy NAPLEX Hypertension Medication Practice Questions to build a solid cardiovascular foundation. For a comprehensive review of all drug classes, the Easy NAPLEX Pharmacology Practice Questions guide provides an excellent overview.

Solved Examples

1. Calculating Ejection Fraction: A patient has an end-diastolic volume (EDV) of 120 mL and an end-systolic volume (ESV) of 72 mL. Calculate the Ejection Fraction (EF) and determine if this qualifies as HFrEF.
   • Step 1: Use the formula $EF = \frac{EDV - ESV}{EDV} \times 100$.
   • Step 2: $EF = \frac{120 - 72}{120} \times 100 = \frac{48}{120} \times 100$.
   • Step 3: $EF = 0.4 \times 100 = 40\%$.
   • Step 4: Since the EF is exactly 40%, this is classified as HFrEF.
2. Switching from ACE Inhibitor to ARNI: A patient is currently taking Lisinopril 20 mg daily and the cardiologist wants to switch them to Sacubitril/Valsartan (Entresto). What is the mandatory washout period?
   • Step 1: Identify the risk of angioedema when combining ACE inhibitors and neprilysin inhibitors.
   • Step 2: Recall the 36-hour washout period required when switching from an ACE inhibitor to an ARNI.
   • Step 3: Instruct the patient to stop Lisinopril and wait at least 36 hours before taking the first dose of Entresto.
3. Monitoring Loop Diuretics: A patient is started on Furosemide 40 mg twice daily for pulmonary edema. Which electrolyte abnormality is most commonly associated with this therapy?
   • Step 1: Identify loop diuretics as "potassium-wasting" agents.
   • Step 2: Recognize that they inhibit the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle.
   • Step 3: Monitor for hypokalemia (low potassium), as well as hypomagnesemia and hyponatremia.

Practice Questions

1. Which beta-blocker is specifically FDA-approved and evidence-based for the treatment of HFrEF?

2. A patient with HFrEF and a serum potassium of 5.2 mEq/L should avoid starting which class of medication due to the risk of life-threatening hyperkalemia?

3. What is the target dose of Lisinopril in the treatment of heart failure according to major clinical trials?

4. Which SGLT2 inhibitor is indicated for the treatment of HFrEF regardless of the presence of Type 2 Diabetes?

5. A patient presents with a dry, hacking cough after starting Enalapril. Which medication class is the most appropriate alternative that avoids this specific side effect?

6. Define the New York Heart Association (NYHA) Functional Class for a patient who has symptoms of heart failure (fatigue, palpitations) with ordinary physical activity but is comfortable at rest.

7. Digoxin is known to reduce which of the following in heart failure patients: Mortality or Hospitalizations?

8. What is the primary mechanism of action of Spironolactone in the context of heart failure?

9. A patient is prescribed Ivabradine (Corlanor). What specific clinical requirement must be met regarding their resting heart rate before initiation?

10. Which medication combination is particularly recommended for African American patients with NYHA Class III-IV HFrEF who remain symptomatic despite optimal GDMT?

Answers & Explanations

1. Carvedilol, Metoprolol Succinate (extended-release), or Bisoprolol. These are the three beta-blockers proven to reduce mortality in HFrEF. Metoprolol tartrate is not evidence-based for this indication.
2. Mineralocorticoid Receptor Antagonists (MRAs) like Spironolactone or Eplerenone. These should generally not be initiated if potassium is $> 5.0 \text{ mEq/L}$.
3. 20 mg to 40 mg daily. While many patients are started on 2.5 mg or 5 mg, the goal is to titrate to these higher doses to achieve the mortality benefits seen in the ATLAS trial.
4. Dapagliflozin (Farxiga) or Empagliflozin (Jardiance). Both have received indications for heart failure regardless of diabetic status based on the DAPA-HF and EMPEROR-Reduced trials.
5. Angiotensin Receptor Blockers (ARBs). ARBs do not inhibit the breakdown of bradykinin, which is the mechanism behind the ACE inhibitor-induced cough. For more on this, check out our Easy NAPLEX Cardiovascular Pharmacology Practice Questions.
6. NYHA Class II. Class I has no limitations; Class II has slight limitations with ordinary activity; Class III has marked limitations with less than ordinary activity; Class IV has symptoms at rest.
7. Hospitalizations. Digoxin has been shown to reduce heart failure-related hospitalizations but does not improve survival (mortality) in HFrEF patients.
8. Aldosterone Antagonism. It blocks the mineralocorticoid receptor, preventing the fibrotic effects of aldosterone on the heart and reducing sodium/water retention in the distal tubule.
9. Resting heart rate $\geq 70 \text{ bpm}$. Ivabradine works by inhibiting the $I_f$ current in the sinoatrial node and is only indicated for patients in sinus rhythm with a heart rate of at least 70 bpm.
10. Hydralazine and Isosorbide Dinitrate (BiDil). This combination has specific evidence for reducing mortality and hospitalizations in the African American population with advanced HFrEF. Check out the AI Question Generator to practice more patient-specific scenarios.

1. Which medication is a Neprilysin Inhibitor found in the combination product Entresto?

• AValsartan
• BSacubitril
• CLosartan
• DEplerenone

Frequently Asked Questions

What is the difference between HFrEF and HFpEF?

HFrEF occurs when the heart's ejection fraction is 40% or less, indicating a pumping problem, while HFpEF occurs when the ejection fraction is 50% or more, indicating a stiffening or filling problem. Management strategies differ significantly, with HFrEF having more established mortality-reducing therapies.

Why is a 36-hour washout period needed when switching from Lisinopril to Entresto?

Both ACE inhibitors and neprilysin inhibitors increase bradykinin levels; using them together or too close in time significantly increases the risk of life-threatening angioedema. The 36-hour window allows the ACE inhibitor to be cleared from the system before starting the ARNI.

Can all beta-blockers be used for heart failure?

No, only three specific beta-blockers (Carvedilol, Metoprolol Succinate, and Bisoprolol) have clinical trial evidence showing they reduce mortality in HFrEF patients. Other beta-blockers like Atenolol or Metoprolol Tartrate are not recommended for this purpose.

How do SGLT2 inhibitors help in heart failure?

SGLT2 inhibitors promote osmotic diuresis and natriuresis, which reduces preload and afterload on the heart, and they may also improve myocardial metabolism and reduce cardiac fibrosis. These effects help prevent heart failure hospitalizations and cardiovascular death.

What are the symptoms of digoxin toxicity?

Early signs of digoxin toxicity include gastrointestinal issues like nausea and vomiting, while more severe toxicity can lead to neurological symptoms such as blurred vision, "yellow-green" halos around lights, and dangerous cardiac arrhythmias. Monitoring serum levels and potassium is vital for prevention.